2025-01-09 - Analysis Report
## Colgate-Palmolive Co (CL) Stock Analysis Report

**1. Performance Comparison and Divergence:**

Colgate-Palmolive Co (CL) is a consumer goods company that manufactures and sells oral hygiene, personal care, and pet products.  The cumulative return for CL is 33.67%, significantly underperforming the S&P 500 (VOO) with a cumulative return of 115.41%. The difference is -81.7%, placing it at the 2.3rd percentile of its historical range of performance relative to the S&P 500.  This indicates consistent underperformance compared to the broader market.  The provided CAGR data shows inconsistent year-over-year performance, ranging from -12% to 32%.  Alpha consistently sits around 0.2, suggesting slight outperformance relative to the market's beta, but this is dwarfed by the overall underperformance compared to the S&P 500.

**2. Recent Price Movement:**

* **Closing Price:** $87.46
* **5-day Moving Average:** $88.62
* **20-day Moving Average:** $91.55
* **60-day Moving Average:** $94.09

The stock is currently trading below all three moving averages, suggesting a downtrend.

**3. Technical Indicators and Expected Return:**

* **RSI (10.89):** Extremely oversold, indicating potential for a bounce.
* **PPO (-0.51):** Negative, confirming the downtrend.
* **Relative Strength Change (20-day):** -2.7%, showing a recent weakening of the relative strength compared to the market.
* **Expected Return (-2015.3%):** This extremely negative figure likely reflects the significant underperformance against the S&P 500 and should be interpreted with caution. It is not a reliable prediction of future returns.  The extremely high negative figure suggests a model error or possibly a misinterpretation of the data's context. A long-term (2+ years) investment strategy requires careful consideration given the current underperformance and low RSI.  Any significant bounce should be viewed with caution. A price of $87.46 is not inherently significant without further context about potential triggers for a price jump or drop.

**4. Recent Earnings Analysis:**

* **Revenue:** Revenue has remained relatively stable around $5 billion for the past four quarters, showing slight fluctuation but no significant growth trend.
* **EPS:** EPS has shown a slight decline from $0.89 in Q2 2024 to $0.86 in Q3 2024. The reported EPS figures are consistent and without major fluctuations. There's no information provided to compare against expectations.

**5. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue is relatively stable, while profit margins have shown a slight downward trend over the last five quarters.
* **Capital and Profitability:** ROE is highly volatile, with extreme values in some quarters. This could indicate significant shifts in equity and may warrant further investigation into the underlying causes.  The large negative ROE in Q3 2023 is cause for concern and needs further analysis to determine the reason.


**6. News and Recent Issues:**

No information on recent earnings news, market outlook, or analyst opinions is provided.  This information is crucial for a complete analysis and should be obtained from financial news sources.

**7. Overall Analysis:**

Colgate-Palmolive is currently significantly underperforming the S&P 500, showing a long-term downtrend. While the RSI suggests potential for a short-term bounce, the negative PPO and overall trend indicate continued weakness.  The extremely volatile ROE and lack of clear revenue growth are concerning. The provided expected return is unreliable and likely flawed.  Additional information on news, analyst opinions, and a more detailed understanding of the unusual financial metrics are needed to form a conclusive opinion.  Considering the extremely negative expected return, further investigation into the underlying reasons for this prediction is essential before any investment decision is made. The current data strongly suggests underperformance relative to the market and raises concerns about the company's financial health and outlook.

**8. Disclaimer:** This analysis is based solely on the provided data.  It is not financial advice and should not be used as the sole basis for investment decisions.  Conduct thorough independent research and consult with a financial advisor before making any investment choices.
